Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $3.5 million.

  • Aytu Biopharma's Change in Accured Expenses fell 5272.23% to $3.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $364000.0, marking a year-over-year increase of 11114.51%. This contributed to the annual value of $886000.0 for FY2025, which is 10967.14% up from last year.
  • Aytu Biopharma's Change in Accured Expenses amounted to $3.5 million in Q4 2025, which was down 5272.23% from -$1.6 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Change in Accured Expenses registered a high of $8.0 million during Q1 2023, and its lowest value of -$14.5 million during Q2 2022.
  • For the 5-year period, Aytu Biopharma's Change in Accured Expenses averaged around -$849100.0, with its median value being -$736500.0 (2024).
  • As far as peak fluctuations go, Aytu Biopharma's Change in Accured Expenses tumbled by 57467.36% in 2022, and later surged by 87987.8% in 2025.
  • Aytu Biopharma's Change in Accured Expenses (Quarter) stood at -$3.9 million in 2021, then soared by 162.73% to $2.5 million in 2022, then tumbled by 48.52% to $1.3 million in 2023, then surged by 474.23% to $7.3 million in 2024, then plummeted by 52.72% to $3.5 million in 2025.
  • Its Change in Accured Expenses stands at $3.5 million for Q4 2025, versus -$1.6 million for Q3 2025 and -$3.1 million for Q2 2025.